RWRebecca Windsor

Rebecca Windsor

*This is an algorithmically generated author record based on publicly available information.

Rebecca Windsor has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Stem cell therapy for rare neurological diseases: translational research opportunities

    by Rebecca Windsor

    Stem cell therapy is being explored for several rare neurological conditions in humans given their potential immunomodulatory, reparative, and regenerative capabilities. Existing standard treatments for most neuroinflammatory and neurodegenerative disorders are primarily palliative, focusing on symptom management rather than addressing underlying disease pathology. The genetic and pathophysiological parallels between many human and animal neurological diseases suggest that companion animals may serve as valuable translational models to drive stem cell research forward. Several rare human neurological conditions with companion animal (particularly canine) correlates include fulminant multiple sclerosis (MS), myasthenia gravis, amyotrophic lateral sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), Dravet and Lennox-Gastaut Syndromes, Globoid Cell Leukodystrophy/Krabbe Disease, viral encephalitis, and glioblastoma multiforme (GBM). Validating the safety and feasibility of stem cell transplantation in companion animal models has enabled the development and expansion of innovative therapies. Stem cell therapy may hold promise as a novel treatment option for some rare and aggressive human and companion animal neurological diseases with limited treatment options.


  • Open Access

    Evaluation of 600 mg/m2 cytarabine arabinoside as treatment for meningoencephalomyelitis of unknown origin in 43 dogs

    by Kara Majors, Samuel D Stewart, Jessica Schmidt, Rebecca Windsor

    Background: Cytarabine arabinoside (CA) is commonly used at 200 mg/m2 to treat dogs with meningoencephalomyelitis of unknown origin (MUO); use of higher doses is anecdotally reported. Hypothesis/Objectives: To describe the clinical outcome in 43 dogs with MUO receiving 600 mg/m2 CA. We hypothesized that high dose CA would be well tolerated, that the majority of dogs with MUO would achieve sustained remission, and that dogs with spinal cord-only MUO or presumptive necrotizing meningoencephalitis (NME) would carry a more guarded prognosis. Animals: Forty-three client-owned dogs with MUO. Methods: Retrospective observational study. Medical records were reviewed at a private practice over a 2.5-year period to identify dogs with MUO with clinical signs 24 months (median 1027 days, range 770–1277 days). Thirteen out of forty-three (30%) dogs were euthanized due to poor disease control (median 17 days, range 1–340 days), including 5/10 (50%) dogs with spinal cord only MUO and 5/5 (100%) dogs with presumptive NME. No serious adverse events were noted with 600 mg/m2 CA. Conclusions and clinical importance: Six hundred mg/m2 CA was well tolerated and effectively controlled disease in most dogs with MUO. Response rate was lower for dogs with spinal cord MUO or presumptive NME.

  • Open Access

    Intravenous allogeneic mesenchymal stromal cell therapy in 13 Pugs with presumptive early necrotizing meningoencephalitis

    by Rebecca C. Windsor, Samuel Stewart, Jennifer M. Cassano, Boaz Arzi, Valentine S. Williams, Linda Black, Mario Mosqueda, Anna Bonfitto, Marcus Naymik, Ignazio Piras, et al.

    Objective: To describe the tolerability and activity of IV allogeneic mesenchymal stromal cell (MSC) therapy in 13 Pugs with presumptive early necrotizing meningoencephalitis (NME). Methods: 255 Pugs were screened from 2021 to 2024 for neurological examination (NE) abnormalities suggestive of early NME. All dogs received a minimum of 2 NEs spaced 2 to 4 weeks apart. An NE score (NES) was assigned at each visit. Magnetic resonance imaging, CSF analysis, and infectious disease testing was obtained in all affected Pugs. Pugs with consistent or progressive NES and MRI or CSF findings supportive of early NME were eligible for MSC therapy. Results: NE abnormalities prior to MSC therapy included spinal hyperesthesia (11 of 13 [85%]), paw placement deficit (11 of 13 [85%]), menace deficit (9 of 13 [69%]), obtundation (9 of 13 [69%]), seizures (7 of 13 [54%]), and ataxia (4 of 13 [31%]). The NES improved in all dogs within 24 hours of the first dose of MSC (mean improvement, 86%). Mild adverse events were noted after 3 of 30 MSC doses (10%). All 13 dogs are currently in remission (follow-up time, 5 to 43 months); 7 of 13 Pugs (54%) remained in remission after MSC therapy alone, and 6 of 13 (46%) required the addition of immunosuppressive therapy. Conclusions: IV allogeneic MSC administration was well tolerated and resulted in immediate clinical benefit in this small cohort of Pugs with presumptive early NME. Strategies to maintain the long-term benefits of MSC therapy require further study. Clinical Relevance: Immunomodulatory MSC therapy may be a potential treatment for neuroinflammatory disease in dogs. Further studies are needed to optimize long-term benefits.


  • Open Access

    Vaccination and Seasonality as Risk Factors for Development of Meningoencephalitis of Unknown Origin in 172 Dogs

    by Maria K. Johnson, Rebecca C. Windsor, Jessica L. Schmidt, David J. Raczek, George E. Moore

    Background: Meningoencephalitis of unknown origin (MUO) is a neuroinflammatory disease that is suspected to be immune-mediated. Vaccination and season inconsistently have been reported as risk factors for development of MUO in dogs, but limited prospectively collected data is available to evaluate these potential risk factors. Objective: Prospectively evaluate the association between vaccination and season and the development of MUO in dogs. Animals: A total of 172 client-owned dogs diagnosed with MUO. Methods: Dogs were enrolled prospectively from August 2021 through July 2023. Signalment, body weight, vaccination history, and season of onset of neurologic signs were recorded. The incidence rate ratio (IRR) of MUO within various post-vaccination windows was statistically compared to a referent window of 451–560 days post-vaccination. The incidence rate (IR) of MUO in each season was compared statistically. Results: Of dogs vaccinated within the previous 450 days, MUO IRR was highest in the first 0–45 days (IRR = 9.14; confidence interval [CI] = 4.04–20.71), followed by 46–90 days (IRR = 4.86; CI = 2.01–11.71) and 91–180 days (IRR = 4.86; CI = 2.15–10.96) post-vaccination compared to the 451–560 day post-vaccination referent window. The MUO IR was slightly more common in the spring (28.5%) and least common in the summer (19.8%). No significant difference in IR between seasons was identified. Conclusions and Clinical Importance: In dogs with potential vaccine-associated MUO, the highest risk to develop MUO may be in the first 45 days post-vaccination. A slowly developing immune response to vaccination over 3–6 months may occur in some dogs. There is no apparent association between season and the development of MUO.


  • Open Access

    An early clinical phenotype of necrotizing meningoencephalitis in the Pug reveals similarities to multiple sclerosis in humans

    by Rebecca Windsor, Samuel Stewart, Matt Huentelman, Stefan Keller, Chand Khanna

    Necrotizing meningoencephalitis (NME) is a fatal neuroinflammatory disease that previously carried a uniformly grave prognosis. Our recent identification of a novel early form of NME in Pugs suggests that disease onset and progression are likely more insidious than previously recognized and provides new hope that early therapeutic intervention may halt disease progression and ultimately prevent or cure NME. This novel perspective also sheds new light on the clinical similarities to multiple sclerosis (MS) in humans and provides a rationale for cross-species translation. The history of recent scientific discoveries in NME and new parallels between MS and NME will be reviewed.


  • Open Access

    A novel meningioma with tyrosine-rich crystals in a 6-year-old Great Dane

    by Kara Majors, Savannah M. Rocha, Rebecca Windsor, Ronald B. Tjalkens, Julia Engelien, Tawfik Aboellail

    A 6-year-old female spayed Great Dane was evaluated for acute onset cluster seizures. Magnetic resonance imaging (MRI) identified a mass in the olfactory bulbs with a large mucoid component caudal to the primary mass. The mass was removed via transfrontal craniotomy and histopathology revealed a tyrosine crystalline-rich, fibrous meningioma with a high mitotic index. Repeat MRI at 6 months showed no detectable tumor regrowth. The dog is clinically normal with no seizures at the time of publication 10 months after surgery. This meningioma subtype is rare in humans. This unique meningioma occurred in a dog of younger age and uncommon breed for intracranial meningioma. Biological progression of this tumor subtype is unknown; however, growth rate might be slow despite the high mitotic index.

  • Open Access

    Brucella canis discospondylitis in 33 dogs

    by Christina Long, Elisabeth Burgers, Christina Copple, Laura Stainback, Rebecca A. Packer, Kelli Kopf, Jessica Schmidt, Samantha Emch, Rebecca Windsor

    Objective: To describe the clinical and imaging findings of 33 dogs withBrucella canisdiscospondylitis (BDS).Animals: 33 client owned dogs from four veterinary specialty hospitals within Colorado and Arizona with at least one positiveB. canistest and spinal diagnostic imaging.Procedures: Retrospective review of signalment, physical and neurological examination findings, laboratory results,B. canisserology, and diagnostic imaging of 33 dogs with BDS. All imaging was reviewed by a board-certified veterinary neurologist. Radiographs were reviewed by a board-certified veterinary radiologist blinded to MRI and CT findings.Results: 31/33 (94%) dogs were 3 months (median = 6 months, mean = 8.2 months, range 5 days−4 years). Fever was seen in only 4/28 (14%) dogs. Multifocal lesions were evident on radiographs in 21/29 (72%) dogs and MRI in 12/18 (67%) dogs. Smooth, round, central end-plate lysis, defined as “hole punch” lesions, were identified radiographically in 25/29 (86%) dogs. Vertebral physitis or spondylitis without discitis was evident on MRI in 7/18 (39%) dogs.Clinical relevance: Dogs with BDS typically present at a young age with a long duration of clinical signs. Identification of radiographic “hole punch” lesions and MRI evidence of vertebral physitis, spondylitis, and paravertebral inflammation without discitis should increase suspicion for BDS. BDS may be increasing in frequency in the southwestern United States, and dogs with signs of chronic spinal pain and/or lameness should be screened forB. canis.


  • Diagnosis and Treatment of a Spinal Intraosseous Keratinized Cyst of L1 in a Dog

    by Jessica Villm, Rebecca Windsor

    An 8 yr old female spayed golden retriever presented for a 3 wk history of progressive pelvic limb ataxia. MRI revealed a well-circumscribed T2-weighted hyperintense, T1-weighted poorly contrast-enhancing extradural mass to the right of the spinal cord at the level of L1 causing severe spinal cord compression. A right-sided hemilaminectomy was performed to remove the mass, and histopathology revealed an intraosseous keratinized cyst. A complete neurologic recovery was made within 2 wk following the surgery. This case illustrates a rare diagnosis and the first case report describing MRI findings and favorable clinical outcome after surgical management of a spinal intraosseous keratinized cyst.

  • Open Access

    A potential early clinical phenotype of necrotizing meningoencephalitis in genetically at-risk pug dogs

    by Rebecca Windsor, Samuel Stewart, Jessica Schmidt, Mario Mosqueda, Ignazio Piras, Stefan M. Keller, Briana Steinmetz, Dori L. Borjesson, Matthew Huentelman, Chand Khanna

    Background: Necrotizing meningoencephalitis (NME) in the pug dogs is a fatal neuroinflammatory disease associated with rapid progression and poor response to conventional immunosuppressive therapy. Diagnosis is typically made after severe neurological abnormalities have manifested. Hypothesis/Objective: Pug dogs at genetic risk for NME might manifest neurological abnormalities before developing pathognomonic clinical signs of NME. Animals: Thirty-six pug dogs less than 4 years of age asymptomatic for NME. Methods: Prospective observational cohort study with germline genome-wide genotyping. Neurological examinations were performed 4 weeks apart to document reproducible findings of central nervous system disease. Magnetic resonance imaging, cerebrospinal fluid analysis, and testing for infectious diseases were performed in all pugs with reproducible abnormalities detected on neurological examination. Results: The overall risk allele frequency in this cohort was 40%; 5 (14%) dogs were high risk, 19 (53%) dogs were medium risk, and 12 (33%) dogs were low genetic risk for NME. Reproducible abnormalities detected on neurological examination were identified in 8/24 (33%) genetically at-risk dogs and 0/12 (0%) low risk dogs. Clinical abnormalities included multifocal spinal pain in 8/8, reduced menace response in 5/8, and lateralizing postural reaction deficits in 5/8 pugs. There was a strong association between genotype risk and the presence of this clinical phenotype (P = .03). Conclusions and Clinical Importance: Our findings suggest the presence of a novel early clinical phenotype of NME in apparently asymptomatic genetically at-risk pugs which might be used to plan early diagnostic and therapeutic clinical trials.


  • Open Access

    Prevalence and clinical features of thoracolumbar intervertebral disc-associated epidural hemorrhage in dogs

    by Jenni Bridges, Rebecca Windsor, Samuel D. Stewart, Lori Fuerher-Senecal, Chand Khanna

    Background: Intervertebral disc-associated epidural hemorrhage (EH) in dogs is a poorly understood neurological condition. Objective: To compare the clinical presentation, magnetic resonance imaging (MRI) changes, and clinical outcome of dogs with acute thoracolumbar intervertebral disc herniation (TL-IVDH) with and without EH. Animals: One hundred sixty client-owned dogs that underwent MRI and hemilaminectomy for acute TL-IVDH at a private practice in Colorado, including 63 dogs with EH and 97 dogs without EH. Methods: Retrospective review of medical record data from 160 dogs presenting sequentially to a single practice with acute TL-IVDH that underwent MRI and hemilaminectomy surgery. Results: Sixty-three of 160 (39%) dogs had confirmed EH. French Bulldogs were significantly overrepresented (23/63; odds ratio [OR]: 4.1; 95% confidence interval [CI]: 1.8-9.0; P < .001) of the EH cases. Dogs with EH were more likely to present with clinical signs less than 48 hours than were dogs without EH (24-48 vs 48-72 hours; OR: 2.4; 95% CI: 1.2-4.6; P = .02) and were more likely to be nonambulatory on presentation (OR: 2.1; 95% CI: 1.0-4.1; P = .04). Dogs with EH were more likely to have <50% cross-sectional spinal cord compression than dogs without EH (OR: 2.3 vs. 0.4; 95% CI: 1.2-4.4 and 0.2-0.9, respectively), longer longitudinal spinal cord compression (3 spaces vs 1 space, P < .001), and greater intrinsic spinal cord change (grade 3/severe vs grade 1/mild; P < .001) based on MRI. The location of the intervertebral disc herniation in French Bulldogs with EH was more likely to be thoracolumbar (OR: 10.8; 95% CI: 2.1-55.7; P = .03). Conclusions and Clinical Importance: French Bulldogs have a high prevalence of intervertebral disc-associated EH. Dogs with EH have a shorter clinical course and are more likely to be nonambulatory on initial presentation.